Non-Hodgkin lymphoma: an update (Q35789262)

10 August 2017

1 reference

title

Non-Hodgkin lymphoma: an update (English)

1 reference

10 August 2017

1 reference

Bryan T Hennessy

1

1 reference

PubMed ID

15172354

10 August 2017

Emer O Hanrahan

series ordinal

2

1 reference

PubMed ID

15172354

10 August 2017

Peter A Daly

series ordinal

3

1 reference

10 August 2017

1 June 2004

1 reference

Lancet Oncology Commission

10 August 2017

1 reference

10 August 2017

5

1 reference

10 August 2017

341-353

1 reference

10 August 2017

6

1 reference

10 August 2017

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Non-Hodgkin's lymphoma in an Asian population: 1968-1992 time trends and ethnic differences in Singapore

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Cancer in children with primary or secondary immunodeficiencies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Viruses in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Gastric lymphoma of mucosa-associated lymphoid tissue and Helicobacter pylori

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

A breakpoint map of recurrent chromosomal rearrangements in human neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

A DNA damage repair mechanism is involved in the origin of chromosomal translocations t(4;11) in primary leukemic cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Molecular diagnosis of the hematologic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Identification of chromosomal copy number changes associated with transformation of follicular lymphoma to diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Radiotherapy for stage I-III nodal low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

High-dose therapy for follicular lymphoma revisited: not if, but when?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Improving outcomes in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Immunochemotherapy in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

International prognostic index-based outcomes for diffuse large B-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Mantle cell lymphoma: established therapeutic options and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Single-Agent Rituximab as First-Line and Maintenance Treatment for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma: A Phase II Trial of the Minnie Pearl Cancer Research Network

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Prognostic factor analysis in mycosis fungoides/Sézary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Impact of high-dose chemotherapy on peripheral T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Angioimmunoblastic T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Peripheral T-cell lymphomas: diagnosis and management

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Immunotherapy for lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

Dendritic cell-based immunotherapy for the treatment of hematological malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2804%2901490-1

7 January 2021

10.1016/S1470-2045(04)01490-1

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15172354